Skye Bioscience & Redx Pharma Unite to Launch Fibrx Therapeutics: A New Chapter in Fibrosis Drug Development
The fibrosis field continues to gain momentum, and one of the latest developments signals growing investor confidence in the next generation of antifibrotic therapies.
In August 2026, Skye Bioscience and Redx Pharma announced plans to combine and form Fibrx Therapeutics, a Nasdaq-listed company dedicated exclusively to developing treatments for fibrotic diseases. The transaction is accompanied by approximately $125 million in financing, positioning the new company to accelerate key clinical development programs and strengthen its presence within the evolving fibrosis landscape.
Why This Matters for the Fibrosis Community
While fibrosis remains a significant driver of morbidity across multiple diseases and organs, treatment options remain limited. As a result, investors and developers alike are increasingly focusing on therapies capable of addressing the underlying fibrotic processes that contribute to disease progression.
The formation of Fibrx Therapeutics reflects this broader trend. By combining Redx Pharma's fibrosis-focused pipeline with access to public market capital and substantial new financing, the company aims to advance innovative therapies targeting fibrotic mechanisms across multiple indications.
The deal also highlights a growing willingness among investors to back fibrosis-focused companies despite a historically challenging development environment, emphasizing continued confidence in the potential of the sector.
Spotlight on RXC008
At the centre of the new company's strategy is RXC008, a GI-restricted pan-ROCK inhibitor being developed for fibrostenotic Crohn's disease. The candidate has already received FDA Fast Track designation and has an open U.S. IND, with a Phase II clinical trial planned. Topline data are expected in the second half of 2028.
Fibrostenotic Crohn's disease represents a significant unmet need. While current therapies primarily target inflammation, they often fail to address the fibrotic scarring that can lead to bowel strictures and surgery. Preclinical data suggest RXC008 may have the potential to reverse fibrotic processes within the gastrointestinal tract, making it an important program to watch.